The stock price of Upstream Bio Inc (NASDAQ: UPB) has jumped by 9.48 compared to previous close of 6.12. Despite this, the company has seen a fall of -12.19% in its stock price over the last five trading days. globenewswire.com reported 2025-03-12 that – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
Is It Worth Investing in Upstream Bio Inc (NASDAQ: UPB) Right Now?
Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UPB is 19.15M, and currently, short sellers hold a 19.39% ratio of that float. The average trading volume of UPB on April 02, 2025 was 250.68K shares.
UPB’s Market Performance
UPB’s stock has seen a -12.19% decrease for the week, with a -10.19% drop in the past month and a -65.09% fall in the past quarter. The volatility ratio for the week is 11.32%, and the volatility levels for the past 30 days are at 10.55% for Upstream Bio Inc The simple moving average for the past 20 days is -17.53% for UPB’s stock, with a -57.17% simple moving average for the past 200 days.
Analysts’ Opinion of UPB
Piper Sandler gave a rating of “Overweight” to UPB, setting the target price at $75 in the report published on November 05th of the previous year.
UPB Trading at -21.27% from the 50-Day Moving Average
After a stumble in the market that brought UPB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.26% of loss for the given period.
Volatility was left at 10.55%, however, over the last 30 days, the volatility rate increased by 11.32%, as shares sank -19.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.09% lower at present.
During the last 5 trading sessions, UPB fell by -12.19%, in comparison to the 20-day moving average, which settled at $8.12. In addition, Upstream Bio Inc saw -59.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UPB starting from Chimovits Erez, who purchase 825,000 shares at the price of $17.00 back on Oct 15 ’24. After this action, Chimovits Erez now owns 4,554,873 shares of Upstream Bio Inc, valued at $14,025,000 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Upstream Bio Inc, purchase 825,000 shares at $17.00 during a trade that took place back on Oct 15 ’24, which means that ORBIMED ADVISORS LLC is holding 4,554,873 shares at $14,025,000 based on the most recent closing price.
Stock Fundamentals for UPB
The liquidity ratio also appears to be rather interesting for investors as it stands at 44.63.
Conclusion
To put it simply, Upstream Bio Inc (UPB) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
